AZD9056 clinical trials
Also written AZD9056.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses AZD9056 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AZD9056
- 3
Studies by the year they started
5 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses AZD9056 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)CompletedPhase 2AstraZenecaNCT00520572Written as AZD9056
- A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis PatientsWithdrawnPhase 1AstraZenecaNCT00920608Written as AZD9056
- A Study to Assess Co-Administered AZD9056 (Steady State) and Simvastatin (Single Dose) in Healthy VolunteersCompletedPhase 1AstraZenecaNCT00736606Written as AZD9056 + simvastatin
- Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056CompletedPhase 1AstraZenecaNCT00700986Written as AZD9056
- AZD9056 Relative Bioavailability StudyCompletedPhase 1AstraZenecaNCT00908934Written as AZD9056 formulation Phase III 50 mg (T)